April
The Dispex WhatsApp group isn’t just expert-led; it’s powered by real-world experience from members facing
the same challenges every day. In recent discussions, members quickly stepped in to support each other
with practical, experience-based answers:
End-of-month processes: Multiple members shared consistent, long-standing approaches to signing
submission forms, giving reassurance based on years (even decades) of no issues.
Stock and availability challenges: Members flagged real-time supply issues, helping others make
informed prescribing and ordering decisions immediately.
High-cost drug confusion: When pricing discrepancies caused uncertainty, peers clarified NHS deals,
reimbursement levels, and the reality of purchase costs – resolving confusion within minutes.
Prescribing criteria queries: Members challenged and sense-checked guideline interpretations, prompting
useful discussion around eligibility and appropriate prescribing routes.
Secondary care and rebate schemes: Insights were shared on how hospital prescribing, ICB rebate
schemes, and manufacturer expectations impact dispensing decisions in practice.
You’re not relying on a few voices from just your practice, you’re tapping into the collective experience of an
entire network, ready to help in real time. Plus, you have direct access to experts who can provide further
guidance or reference the appropriate authorities when required.
Across recent discussions, Philip provided further guidance on key profitability and compliance topics, from
how to correctly order high-cost drugs like Denosumab using e-CASS, to ensuring practices maximise
margin by prescribing generically and avoiding common ordering mistakes.
He also broke down complex financial decisions in real- time. On Inclisiran, Philip directed members to
definitive guidance, helping clarify confusion around pricing and reimbursement. On Repatha, he explained
exactly when practices make a profit (£22.40) versus a loss (£45.64), giving members clear, actionable
insight to protect income.
When clinical and regulatory questions arose, Philip provided authoritative answers grounded in the Drug
Tariff – even advising on when private prescribing may be appropriate and how to balance patient
care with financial considerations. Alongside this, Ankit contributed to keeping members updated
with key Dispex resources and tools, ensuring practices stay ahead with the latest pricing updates.
If you’re not in the group, you’re missing fast peer support and expert-led answers that directly impact your
profitability, compliance and confidence!
Click here to login and register today! You may register multiple mobile numbers as required. However, it is
your responsibility to obtain the necessary consent from your colleagues before adding their numbers. All
users retain the right to unregister at any time.
